Australia Drug Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Australia Drug Delivery Devices Market Trends and Insights

High Burden of Chronic Diseases and Ageing Population

Australia’s 1.3 million people living with diabetes in 2024 generated AUD 3.9 billion in direct health spending aihw.gov.au. Three-quarters of adults were dispensed at least one PBS medicine, and more than 85% of those with chronic conditions required ongoing pharmacotherapy.^{[1]Australian Bureau of Statistics, “Health Conditions and Risks,” abs.gov.au}Age-related physiological changes alter drug absorption and clearance, heightening demand for delivery formats that optimise dosing precision and safety. Manufacturers that tailor devices to geriatric needs—larger buttons, audible cues, and connected adherence alerts—stand to gain as the senior cohort expands.

Government and Market Players Support for At-home Care & Remote Drug Delivery

Victoria’s Better at Home program channels AUD 698 million into virtual and in-home healthcare, serving more than 15,000 people a year.^{[2]Victorian Department of Health, “Better at Home Initiative,” health.vic.gov.au} Queensland added AUD 27 million for similar services in its 2024-25 budget. Hospital-at-home models have lowered care costs by 30% while maintaining or improving outcomes, leading payers to reimburse home episodes at inpatient rates commonwealthfund.org. These policies create fertile ground for self-use injectors, wearable pumps, and connected inhalers that help patients manage therapy outside acute facilities.

Rising Penetration of Biosimilars and Targeted Therapies Requiring Novel Delivery Formats

Novartis opened a dedicated radioligand-therapy plant in 2024, underscoring demand for precise oncology delivery technologies. Researchers at the University of Sydney advanced an oral insulin tablet that releases drug only in response to blood-glucose changes, potentially displacing subcutaneous injections for many patients.^{[3]University of Sydney, “Nanotech Opens Door to Future of Insulin Medication,” sydney.edu.au} As biologics and conjugated molecules enter late-stage pipelines, innovators are redesigning delivery platforms to maintain molecule stability, handle high viscosity, and improve patient acceptance.

Digital Health Integration with Connected Injectors & Pumps

The National Digital Health Strategy (2023-2028) prioritises FHIR-based data standards and pledges AUD 325.7 million to upgrade e-prescribing, medication management, and device interoperability. Wider use of My Health Record supports real-time adherence tracking and remotely managed dose titration. Technology forums such as the 2025 C3.0 summit place connectivity, cybersecurity, and clinical governance at the centre of drug-device innovation.

Stringent TGA Combination-Product Compliance Costs

Application fees for new chemical entities included in a device run to AUD 18,872, with evaluation charges of AUD 76,055 and annual levies topping AUD 1,500 for Class III devices. These rising costs weigh heavily on start-ups and academic spin-outs, delaying market entry and, in some cases, redirecting R&D overseas.

Needlestick Injury Litigation and Risks Associated with Various Devices

Despite falling numbers of people injecting drugs, incidence of blood-borne infections linked to reused needles has risen, driving higher liability risk for device manufacturers. Government guidelines now demand stricter infection-control protocols and reporting, increasing compliance overhead for hospitals and aged-care facilities.

Segment Analysis

By Device Type: Injectable Devices Lead While Transdermal Patches Surge

Injectable systems held 31.63% of the Australia drug delivery devices market share in 2024, a position cemented by growing biologics use and rising chronic-disease prevalence. Connected pen injectors that transmit dosage logs to clinician dashboards are gaining traction among endocrinologists and rheumatologists. The Australia drug delivery devices market size attached to transdermal patches is projected to grow at 12.29% CAGR between 2025 and 2030, spurred by microneedle breakthroughs that improve payload capacity without compromising comfort. Collaboration between the Transdermal and Transmucosal Drug Delivery Research Group and Bionyeri Pty Ltd created a microneedle patch for acute pain episodes, illustrating domestic innovation.

Infusion-pump makers are integrating Bluetooth and closed-loop algorithms in anticipation of a national subsidy for insulin pumps proposed to begin mid-2025. Implantables, ocular inserts, and nasal devices round out the portfolio, each targeting niche clinical requirements. A recent health-technology assessment found intrathecal pumps improve quality of life for refractory cancer pain, though upfront costs remain high.

Note: Segment shares of all individual segments available upon report purchase

By Route of Administration: Injectables Dominate While Oral Mucosal Delivery Accelerates

Injectables delivered 44.57% of 2024 revenue within the Australia drug delivery devices market. High therapy adherence rates and predictable pharmacokinetics keep parenteral administration the default for many biologics. Inhalation devices account for a sizeable fraction, supported by ongoing upgrades to dry-powder carriers for obstructive-airway disease. The oral-mucosal channel is forecast to post a 10.23% CAGR as developers exploit sublingual routes to bypass first-pass metabolism. 

Transdermal technologies continue to benefit from work on novel permeation enhancers and herbal patches that reduce gastrointestinal side effects. Nasal formulations appeal to neurologists for rapid central-nervous-system access; nanoparticle-gel hybrids recently showed 86%–96% encapsulation efficiency, signalling commercial promise.

By Application: Cancer Leads While Diabetes Shows Strongest Growth

Cancer uses generated 28.67% of 2024 revenue, reflecting a need for precise, often multi-modality dosing. Bacterial nanotechnology that steers chemotherapeutics to tumours exemplifies next-generation targeting approaches. The Australia drug delivery devices market size attributed to diabetes therapies is on track for a 10.74% CAGR, driven by automated insulin delivery and continuous-glucose-monitoring integration. Atmospheric-pressure studies confirm device durability during air travel, an important consideration for Australia’s mobile population. Cardiovascular, infectious-disease, and paediatric segments also add incremental demand, with RSV preventives already lowering hospitalisations in pilot states.

Note: Segment shares of all individual segments available upon report purchase

By End User: Hospitals Dominate While Home Healthcare Expands Rapidly

Hospitals absorbed 49.13% of total 2024 sales, buoyed by AUD 9.3 billion in fresh state-level hospital funding and nine new facilities slated to open by 2026. Ambulatory surgical centres, known for day-case procedures, are quick to adopt fast-onset anaesthetic patches and programmable infusion pumps to keep discharge times low.

Homecare remains the fastest-growing channel with an 11.51% projected CAGR. The Better at Home program and equivalent telehealth funding streams promote self-managed therapy using connected devices that alert nurses to out-of-range metrics. Victoria’s hospital-at-home scheme demonstrated 30% cost reductions and equal or better outcomes compared with inpatient stays. Specialty clinics and field-based nursing services leverage similar technologies when treating rheumatology and oncology patients outside tertiary centres.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

Urban states dominate demand for sophisticated platforms, yet regional areas increasingly benefit from digital-health advances. Victoria’s AUD 698 million commitment to remotely delivered care places the state at the forefront of connected treatment models, driving higher per-capita adoption of wearable injectors. Queensland’s AUD 28.9 billion health budget, including AUD 27 million for virtual-care initiatives, underlines northern states’ pursuit of similar tools. 

Nationwide, the Australia drug delivery devices market benefits from FHIR-compliant data exchange that enables tele-consultations even in sparsely populated areas. The strategy’s focus on secure pharmacovigilance systems means new devices must integrate seamlessly with My Health Record, a requirement shaping supplier selection criteria for rural pharmacies.

Western Australia and Queensland’s infant RSV programs highlight the growing role of state vaccination policies in shaping device adoption. Long-acting monoclonal injections administered through community clinics reduced hospital admissions costing as much as AUD 17,120 per child. As similar preventive measures roll out nationwide, demand for paediatric-friendly autoinjectors and low-dead-space syringes is rising.